OTCMKTS:BVNRY Bavarian Nordic A/S (BVNRY) Stock Price, News & Analysis $7.82 -0.08 (-1.01%) As of 03:46 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesShort InterestBuy This Stock About Bavarian Nordic A/S Stock (OTCMKTS:BVNRY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bavarian Nordic A/S alerts:Sign Up Key Stats Today's Range$7.80▼$7.9150-Day Range$6.84▼$8.1052-Week Range$6.60▼$14.60Volume4,418 shsAverage Volume8,750 shsMarket Capitalization$1.85 billionP/E Ratio11.33Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBavarian Nordic A/S is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. Written by Jeffrey Neal JohnsonRead More… Receive BVNRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bavarian Nordic A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address BVNRY Stock News HeadlinesBavarian Nordic A/S: Bavarian Nordic's Chikungunya Vaccine Receives Recommendation from U.S. CDC's Advisory Committee on Immunization Practices (ACIP)April 17, 2025 | finanznachrichten.deBavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)April 17, 2025 | finance.yahoo.comMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.May 1, 2025 | Stansberry Research (Ad)Bavarian Nordic gets ACIP recommendation for its chikungunya vaccineApril 17, 2025 | seekingalpha.comBavarian Nordic's Chikungunya Vaccine Receives Recommendation from U.S. CDC's Advisory Committee on Immunization Practices (ACIP)April 16, 2025 | globenewswire.comCorrection: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/SApril 9, 2025 | globenewswire.comCorrection: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/SApril 9, 2025 | globenewswire.comResolutions of the Annual General Meeting 2025 of Bavarian Nordic A/SApril 9, 2025 | globenewswire.comSee More Headlines BVNRY Stock Analysis - Frequently Asked Questions How have BVNRY shares performed this year? Bavarian Nordic A/S's stock was trading at $8.7060 at the beginning of the year. Since then, BVNRY shares have decreased by 10.2% and is now trading at $7.82. View the best growth stocks for 2025 here. How were Bavarian Nordic A/S's earnings last quarter? Bavarian Nordic A/S (OTCMKTS:BVNRY) announced its quarterly earnings data on Wednesday, March, 5th. The company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.40 by $0.07. The firm had revenue of $299.48 million for the quarter, compared to analyst estimates of $264.06 million. Bavarian Nordic A/S had a net margin of 18.33% and a trailing twelve-month return on equity of 10.65%. How do I buy shares of Bavarian Nordic A/S? Shares of BVNRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/05/2025Today5/01/2025Next Earnings (Estimated)5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:BVNRY CIKN/A Webwww.bavarian-nordic.com Phone(453) 326-8383Fax45-3326-8380Employees1,379Year Founded1994Profitability EPS (Most Recent Fiscal Year)$0.60 Trailing P/E Ratio11.45 Forward P/E Ratio11.79 P/E GrowthN/ANet Income$214.20 million Net Margins18.33% Pretax Margin18.51% Return on Equity10.65% Return on Assets7.90% Debt Debt-to-Equity RatioN/A Current Ratio1.69 Quick Ratio0.98 Sales & Book Value Annual Sales$1.02 billion Price / Sales1.82 Cash Flow$1.89 per share Price / Cash Flow4.17 Book Value$6.41 per share Price / Book1.23Miscellaneous Outstanding Shares236,565,000Free FloatN/AMarket Cap$1.87 billion OptionableNot Optionable Beta1.55 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:BVNRY) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behin...Stansberry Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bavarian Nordic A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Bavarian Nordic A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.